LAB — Standard BioTools Inc.

Summary of Standard BioTools, Inc. Q1 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $40.8 million, down 10% year-over-year, aligning with expectations.
• Consumables Revenue: $14.5 million, down 16% year-over-year, impacted by lower demand in the Americas.
• Instruments Revenue: $7.8 million, up 24% year-over-year, driven by growth in the spatial proteomics segment.
• Services Revenue: $17.6 million, down 16% year-over-year, primarily due to a decline in lab services.
• Net Loss: $26 million, an improvement from a loss of $32.2 million in Q1 2024.
• Adjusted EBITDA: Loss of $16.9 million, improved from a loss of $23.7 million in Q1 2024.
• Cash Position: $261 million in cash and equivalents, with no material debt.
• Operating Expenses: Non-GAAP operating expenses decreased by 22% year-over-year to $38.6 million.

2. Strategic Updates and Business Highlights

• The company is focused on improving operational efficiency through the Standard BioTools Business System (SBS), which has led to significant cost reductions.
• Recent product launches include the SomaScan offering and the CyTOF-XT Pro, aimed at enhancing the company's position in proteomics.
• The partnership with Illumina is expected to expand the reach of SomaScan, although significant revenue from this collaboration is not anticipated until 2026.
• The integration of SomaLogic has been successful, with over $80 million in cost reductions achieved since the merger.

3. Forward Guidance and Outlook

• Full-Year Revenue Guidance: Maintained at $165 million to $175 million, with expectations for a back-weighted revenue distribution.
• Americas Academic Revenue: Anticipated mid-teens percentage decline, reflecting ongoing funding challenges.
• Tariff Impact: Estimated low single-digit millions impact on gross margin and adjusted EBITDA, with plans to manage costs through pricing strategies.

4. Bad News, Challenges, or Points of Concern

• Market Headwinds: Continued challenges in U.S. academia and government funding, leading to delays in orders and project funding.
• Revenue Declines: Notable decreases in consumables and services revenue due to project timing and funding uncertainties.
• Tariff Complexity: New tariffs have added operational challenges, although the company views them as manageable.
• Dependence on Large Customers: Revenue variability remains due to reliance on a few large accounts, which can obscure performance trends.

5. Notable Q&A Insights

• Revenue Split: Management indicated that the revenue split between the first and second halves of the year is expected to be driven by internal funnel metrics rather than traditional seasonality.
• Instrument Demand: Positive growth in the sales funnel for instruments, particularly the Hyperion XTi, with no significant pull-forward effects noted.
• M&A Strategy: The company remains committed to pursuing strategic acquisitions, with a disciplined approach to identifying opportunities in a changing market.
• Biopharma Market: Healthy growth observed in the biopharmaceutical sector, with no significant changes in spending patterns reported.

Overall, Standard BioTools is navigating a challenging market environment while focusing on operational improvements and strategic growth initiatives, particularly in proteomics and through partnerships.